Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanogen to Host Fourth Quarter Conference Call and Webcast on February 20, 2007

Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, will host a conference call on Tuesday, February 20, 2007 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2006 fourth quarter financial results. The financial results press release will be issued at close of market on February 20. Interested investors and others may participate in the conference call by dialing 877-407-9205 for US/Canada participants and 201-689-8054 for international participants.

Nanogen to Host Fourth Quarter Conference Call and Webcast on February 20, 2007

SAN DIEGO, CA | Posted on February 19th, 2007

Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at , and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on February 20, and can be accessed via telephone at 877-660-6853 for US/Canada participants and (201) 612-7415 for international participants. The account number, 286, along with the conference ID, 231215, will be required to listen to the playback.


About Nanogen
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChipģ electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogenís website at .

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

For more information, please click here

Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Suzanne Clancy, Corporate Communications, 858-410-4688

Porter Novelli Life Sciences
Kim Richards, Media & Investor Relations, 619-849-5377

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Extracellular vesicles could be personalized drug delivery vehicles March 15th, 2018

Scientists Use Nanotechnology to Detect Molecular Biomarker for Osteoarthritis March 13th, 2018

Polymer nanoparticle shows ability to locate and treat breast tumors March 13th, 2018


Design approach developed for important new catalysts for energy conversion and storage: New method could aid in design of pharmaceuticals and optical and data storage materials March 21st, 2018

RIT researchers improve fabrication process of nano-structures for electronic devices: Use of indium gallium phosphide with I-MacEtch processing shows promise for more cost effective fabrication and increased performance in devices from photonics to telecommunications March 20th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Leti and Inac Show Path to Creating Building Blocks of Quantum Processors With 28Si isotope in a CMOS Line: Fabrication of Isotopically Enriched, Industry-Compatible Wafers Points Way To Realizing Silicon Spin Quantum Bits with Enhanced Fidelity March 20th, 2018

Financial Reports

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results February 3rd, 2018

Nanometrics Announces Preliminary Results for the Third Quarter of 2017: Quarterly Results Impacted by Delays in Revenue Recognition on Multiple Systems into Japan October 12th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project